

Organic Preparations and Procedures International: The New Journal for Organic Synthesis

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/uopp20>

A PRACTICAL SYNTHESIS OF 4-ACETYL-2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPINE

Qingjie Zhao ^a, Haihong Li ^b, Fuqiang Zhu ^b, Hongli Guo ^a & Jingshan Shen ^{a b}

^a Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, PR CHINA

^b Topharman Shanghai Co., Ltd., Shanghai, 201209, PR CHINA E-mail:

Published online: 18 Feb 2009.

To cite this article: Qingjie Zhao, Haihong Li, Fuqiang Zhu, Hongli Guo & Jingshan Shen (2008) A PRACTICAL SYNTHESIS OF 4-ACETYL-2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPINE, Organic Preparations and Procedures International: The New Journal for Organic Synthesis, 40:5, 490-493, DOI: [10.1080/00304940809458113](https://doi.org/10.1080/00304940809458113)

To link to this article: <http://dx.doi.org/10.1080/00304940809458113>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &

A PRACTICAL SYNTHESIS OF 4-ACETYL-2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPINE

Submitted by Qingjie Zhao,[†] Haihong Li,[‡] Fuqiang Zhu,[‡] Hongli Guo,[†]
(05/03/08) and Jingshan Shen^{*,†,‡}


[†] Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Shanghai 201203, P. R. CHINA

[‡] Topharman Shanghai Co., Ltd.

Shanghai 201209, P. R. CHINA

E-mail: jsshshen@mail.shcnc.ac.cn


2,3,4,5-tetrahydro-1H-1,4-benzodiazepine (**3**) and 4-acetyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine (**4**) as important intermediates are used in many aspects such as 5-HT_{2C} receptor agonists for the treatment of obesity,¹ dopamine D₃ receptor ligands,² inhibitors of phenylethanolamine *N*-methyltransferase,³ inhibitors of Farnesyl transferase,⁴ etc. The most applicable existing approach for preparation of title compound **1** involved synthesis of key intermediate benzodiazepinedione **2** which was obtained by condensation of isatoic anhydride⁵⁻⁷ with glycine or glycine ethyl ester hydrochloride (R = Et) at elevated temperature.^{4,8} Then compound **2** was reduced with lithium aluminum hydride (LAH) in THF to give **3**,⁹⁻¹⁰ which was monoacetylated with acetic anhydride in triethylamine to form **4** (Scheme 1).¹¹



Scheme 1

Though the route seems elegant and straightforward, the process suffers from several disadvantages such as the use of expensive LAH and anhydrous THF; in addition, LAH is not a good choice due to safety concerns because it is highly flammable and moisture sensitive and the work-up procedure for LAH is not very convenient as small deviations will result in unfilterable suspended solids. These factors made the process less viable for commercial production. We report here a short, economic, and efficient route to **4** free from undesirable reagents (LAH) and conditions (high temperature) starting from commercial available 2-nitrobenzaldehyde (**5**) in an overall yield of around 60% (Scheme 2).

Of all the methods used for the synthesis of **6**, the reaction of aromatic aldehydes with amines followed by reduction of the intermediate imines with NaBH₄ proved to be the best one with respect to economy and yields.¹² Thus condensation of 2-nitrobenzaldehyde



Scheme 2

with 2-chloroethylamine hydrochloride at room temperature in methanol gave the Schiff's base which was reduced with less expensive KBH_4 to give compound 6, isolated as its hydrochloride by crystallization with $\text{HCl(g)}/\text{ethanol}$ in 90% yield. Although reduction of nitro group could be achieved by many metal-acid reducing systems such as Sn/HCl and Zn/HCl , the use of the latter two reagents gave 3 in poor yields presumably because these reducing agents are too potent. Thus mild reducing conditions were explored and reduction of the nitro group was achieved with zinc in ethanol, albeit requiring more than 24 h to be complete at room temperature. When the reaction temperature was raised to 45–50°C, the reduction was complete in 5 h to give cyclization product 3 as the crystalline dihydrochloride salt in 74% yield. Acylation of the more basic 4-amine to form 1 was originally accomplished by condensation with acetic anhydride in the presence of triethylamine in ether;¹¹ however, the yield was low. An improved yield was obtained when the reduction was carried out by addition of acetyl chloride to a solution of 3 in CH_2Cl_2 in the presence of pyridine at 0°C; after 2 h at room temperature with stirring, the organic layer was evaporated to give an oil which was crystallized in ether to give 4 in 90% yield.

In summary, we have developed a feasible route for the scaled up preparation of the title compound 4 from 2-nitrobenzaldehyde. Undesirable reagents and conditions were eliminated and the process proceeded very well in our pilot plant.

EXPERIMENTAL SECTION

All reagents were commercially obtained and used as received. ^1H NMR spectra were obtained on a Bruker AMX-400/600 at 300 MHz or 400 MHz using TMS as an internal standard. ^{13}C NMR spectra were obtained from a Gemini-300 spectrometer in deuterated solvents with TMS as an internal standard at room temperature. The melting points were determined by using the capillary method on a Buchi-510 melting point apparatus. The mass spectrum was recorded on a Finnigan MAT-95/711 spectrometer.

N-(2-Chloroethyl)-2-nitrobenzylamine (6).—A solution of 2-nitrobenzaldehyde (300 g, 2 mol) and 2-chloroethylamine hydrochloride (248 g, 2.16 mol) in ethanol (1.5 L) was stirred for 3 h at ambient temperature. KBH_4 (49.8 g, 0.92 mol) was then added slowly at 0–10°C in four portions at intervals of 10 min and stirring continued for 2 h. The reaction mixture was evaporated to give

an oil and a saturated aqueous sodium hydrogen carbonate was added to the mixture to adjust the pH of the solution to 9-10, and extracted with methylene chloride (3 x 300 mL). The combined organic layers were washed with brine (500 mL), and dried over anhydrous Na₂SO₄. After removal of the drying agent, the solvent was evaporated under reduced pressure and the residue, so obtained, was treated with HCl(g)/ethanol to give **7** as the colorless crystalline hydrochloride (447 g, 90%). An analytical sample was obtained by recrystallization from ethanol, mp ~210°C (dec.). ¹H NMR (CDCl₃): δ 8.20 (d, 1H, J = 8.2 Hz), 7.87 (m, 2H); 7.71 (t, 1H, J = 7.3 Hz), 4.50 (s, 1H); 3.99 (t, 1H, J = 6.1 Hz), 3.42 (t, 1H, J = 6.3 Hz). ¹³C NMR (CDCl₃): 39.18, 47.33, 48.53, 125.28, 127.04, 130.77, 133.47, 134.33, 148.43. HRMS (EI): Exact Mass: Calcd for C₉H₁₀ClN₂O₂ 213.0431. Found 213.0423.

Anal. Calcd for C₉H₁₂Cl₂N₂O₂: C, 43.05; H, 4.82; N, 11.16. Found: C, 43.22; H, 4.82, N, 10.99

2,3,4,5-Tetrahydro-1H-benzodiazepine (3).— N-(2-Chloroethyl)-2-nitrobenzylamine hydrochloride (375 g, 1.5 mol) was dissolved in ethanol (1.8 L), zinc powder (192 g, 2.94 mol) was added in portions. The resulting mixture was heated to 40-45°C for 3 h. After completion of the reaction (monitored by TLC), the mixture was filtered, and the filtrate was concentrated to give an oil. H₂O (1.2 L) was added, and the pH of aqueous layer was adjusted to 9-10 with 1 M aqueous NaOH solution and extracted with methylene chloride (2 x 600 mL). The organic layers were combined, and dried over Na₂SO₄, and evaporated under reduced pressure to give an oil. A solution of HCl(g)/ethanol was added with cooling whereupon, **3** precipitated as its colorless dihydrochloride (244 g, yield 74%). An analytical sample was obtained by recrystallization from ethanol, mp 96-97°C (*lit.*⁹ 95-97°C).

4-Acetyl-2,3,4,5-tetrahydro-1H-benzodiazepine (4).— Acetyl chloride (70 mL, 0.99 mol) was added dropwise to a methylene chloride solution (1 L) of 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine dihydrochloride (220 g, 1 mol) and pyridine (160 mL) at 0°C. After stirring for 2 h at room temperature, the resulting mixture was poured into ice-water and the organic layer was separated and the aqueous layer was extracted with methylene chloride (2 x 400 mL). The organic layers were combined and dried over Na₂SO₄ and evaporated on a rotary evaporator under reduced pressure to give crude product as an oil. Crystallization from ether provides pure title compound (171 g, purity 98%, 90% yield) as a colorless solid, mp 85-86°C (*lit.*¹¹ 84-86°C). The spectroscopic data correspond to those reported in literature.¹¹

REFERENCES

1. A. L. Sabb, R. L. Vogel, G. S. Welmaker, J. E. Sabalski, J. Coupet, J. Dunlop, S. Rosenzweig-Lipson and B. Harrison, *Bioorg. Med. Chem. Lett.*, **14**, 2603-2607 (2004).
2. U. R. Mach, A. E. Hackling, S. Perachon, S. Ferry, C. G. Wermuth, J.-C. Schwartz, P. Sokoloff and H. Stark, *ChemBioChem.*, **5**, 508 (2004).
3. G. L. Grunewald, V. H. Dahanukar, P. Ching and K. R. Criscione, *J. Med. Chem.*, **39**, 3539 (1996).

4. C. Ding, R. Batorsky, R. Bhide, H. J. Chao, Y. Cho, S. Chong, J. Gullo-Brown, P. Guo, S. H. Kim, F. Lee, K. Leftheris, A. Miller, T. Mitt, M. Patel, B. A. Penhallow, C. Ricca, W. C. Rose, R. Schmidt, W. A. Slusarchyk, G. Vite, N. Yan, V. Manne and J. T. Hunt, *J. Med. Chem.*, **42**, 5241 (1999).
5. Y. R. Rao, M. Mapuji and S. N. Mahapatra, *Org. Prep. Proc. Int.*, **14**, 199 (1982).
6. T. Nagasaka and Y. J. Koseki, *J. Org. Chem.*, **63**, 6797 (1998).
7. J.-M. Huang, H. Chen and R.-Y. Chen, *Synth. Commun.*, **32**, 2215 (2002).
8. O. Lack and R. E. Martin, *Tetrahedron Lett.*, **47**, 8207 (2005).
9. D. H. Kim, *J. Med. Chem.*, **20**, 209 (1977).
10. M. Uskoković, J. Iacobelli and W. Wenner, *J. Org. Chem.*, **27**, 3606 (1962).
11. D. H. Kim, *J. Heterocycl. Chem.*, **13**, 1187 (1976).
12. R. P. Tripathi, N. Saxena, V. K. Tiwari, S. S. Verma, V. Chaturvedi, Y. K. Manju, A. K. Srivastva, A. Gaikwad and S. Sinha, *Bioorg. Med. Chem.*, **14**, 8186 (2006).

SYNTHESIS OF 3-(2-ARYL-1H-INDOL-3-YL)-4-AROYL-5-ARYLISOXAZOLINES

Submitted by Vijai N. Pathak[†], Meenakshi Jain* and Anjali Tiwari
(03/08/08)

*Centre of Advanced Studies, Department of Chemistry,
University of Rajasthan, Jaipur-302 004, INDIA
e-mail: pathakvijain@yahoo.com*

Isoxazoles are useful as intermediates in organic synthesis and possess a broad range of biological activities such as antibacterial and antifungal,¹ antiinflammatory,² antiviral,³ herbicidal,⁴ neurotropic and antitumor,⁵ vasodilating, anticoagulant and cardio-protective activities,⁶ glycoprotein IIb/ IIIa antagonistic,⁷ anti-HIV and antidepressant activities.⁸ They also act as novel inhibitors of cyclooxygenase-2 with analgesic activity⁹ and inhibitors of human leukocyte elastase (HLE) and cathepsin G (Cath G).¹⁰ Isoxazoles have been utilized as scaffolds for peptidomimetics,¹¹ and core structures in medicinal chemistry. Indole derivatives also constitute an important class of therapeutic agents in medicinal chemistry including anticancer,¹² antioxi-